Anika Therapeutics (ANIK) Set to Announce Quarterly Earnings on Wednesday

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Anika Therapeutics to post earnings of ($0.19) per share for the quarter. Anika Therapeutics has set its FY 2024 guidance at EPS.Individual interested in participating in the company's earnings conference call can do so using this link.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.20. Anika Therapeutics had a negative return on equity of 2.10% and a negative net margin of 49.60%. The company had revenue of $42.97 million for the quarter, compared to analyst estimates of $41.51 million. On average, analysts expect Anika Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Anika Therapeutics Stock Performance

ANIK traded up $0.60 on Wednesday, hitting $26.49. The company had a trading volume of 71,391 shares, compared to its average volume of 78,111. The stock has a fifty day moving average price of $25.52 and a 200-day moving average price of $23.21. Anika Therapeutics has a 12-month low of $16.54 and a 12-month high of $28.13. The stock has a market capitalization of $392.85 million, a price-to-earnings ratio of -4.58, a P/E/G ratio of 2.32 and a beta of 0.76.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Barrington Research lifted their target price on Anika Therapeutics from $29.00 to $37.00 and gave the company an "outperform" rating in a research note on Thursday, March 14th. Stephens reiterated an "equal weight" rating and issued a $22.00 target price on shares of Anika Therapeutics in a research note on Thursday, March 14th. Finally, StockNews.com upgraded Anika Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, March 14th.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.